Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 8th April 2015
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Joint strategy to benefit human and animal health
Syringe
The document under consultation outlines joint key priorities for the network.

Draft document outlines priorities for next five years

The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have released the 'EU Medicines Agencies Network Strategy to 2020'.

The document focuses on areas where collaboration within the network can make a difference to human and animal health in Europe in the next five years.

It is presented, for the first time, as a single strategy for the entire network - reflecting the need for a coordinated approach.

Arranged under four key themes, the strategy focusses on:

  • Human health
  • Animal and human health in relation to veterinary medicines,
  • Optimising the operation of the network
  • The global regulatory environment
It also includes a high level strategy to achieve these priorities.  

EMA and HMA say that the need to further strengthen the collaboration between the members of the network and work together towards achieving agreed goals has become more urgent in recent years.

"Europe faces the global threat of antibiotic resistance, and needs to be prepared for emerging epidemics," a spokesperson said.  "At the same time, the healthcare needs of patients in Europe are changing.  

"Advancements in science and medicine mean that new and more complex medicines are being developed, which may bring opportunities for personalised medicines and more treatments for rare diseases. Patients also require timely access to new, beneficial and safe medicines.

"The globalisation of the pharmaceutical industry means that greater collaboration with regulators beyond the European Union (EU) is essential to assure the supply of safe, effective and good quality medicines for humans and animals."

To view the Strategy visit www.ema.europa.eu. Stakeholders are invited to send their comments to EUnetworkstrategy@ema.europa.eu by 30 June 2015.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.